Literature DB >> 430485

Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue.

D E Nichols, R Woodard, B A Hathaway, M T Lowy, K W Yom.   

Abstract

An hallucinogen analogue, trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine (DMCPA), was resolved into ints two enantiomers by fractional crystallization of salts with d- or l-O,O-dibenzoyltartaric acid. A comparison of the ORD and CD curves of the N-5-bromosalicylidene derivatives of trans-2-phenylcyclopropylamine of known absolute configuration and of the title compound established the stereochemistry of the latter to be (1R,2S)-(-) and (1s,2r)-(+). We have earlier shown that the (-) isomer shows selective behavioral effects in cats and mice. In present study it was found that the (-) isomer selectively elicits rabbit hyperthermia when compared with the (+) isomer. In view of the stereoselective ability of the (-) isomer to elicit hallucinogen-like behavioral profiles in these animal models, the proof of absolute configuration lends further support to a new model which interrelates the active binding, conformation of phenethylamine hallucinogens to that of serotonin and tryptamines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 430485     DOI: 10.1021/jm00190a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor.

Authors:  James J Chambers; David E Nichols
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

2.  trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family.

Authors:  Adam Pigott; Stewart Frescas; John D McCorvy; Xi-Ping Huang; Bryan L Roth; David E Nichols
Journal:  Beilstein J Org Chem       Date:  2012-10-08       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.